T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
Robert J. Motzer,Toni K. Choueiri,David F. McDermott,Thomas Powles,Yann Vano,Saurabh Gupta,Jin Yao,Celine G. Han,Ron Ammar,Simon Papillon-Cavanagh,Shruti Shally Saggi,M. Brent McHenry,Petra Ross-Macdonald,Megan Wind-Rotolo +13 more
TL;DR: The exploratory analyses reveal relationships between molecular biomarkers and provide supportive data on how the inflammation status of the tumor microenvironment may be important for identifying predictive biomarkers of response and survival with combination immunotherapy in patients with RCC.
Journal ArticleDOI
The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.
Christopher J.D. Wallis,James W.F. Catto,Antonio Finelli,Adam Glaser,John L. Gore,Stacy Loeb,Todd M. Morgan,Alicia K. Morgans,Nicolas Mottet,Richard D Neal,Tim O'Brien,Anobel Y. Odisho,Thomas Powles,Ted A. Skolarus,Ted A. Skolarus,Angela B. Smith,Bernadett Szabados,Zachary Klaassen,Daniel E. Spratt +18 more
TL;DR: An evidence-informed, expert-derived review of genitourinary cancer care moving forward following the initial COVID-19 pandemic to raise concerns that physicians and health administrators must consider in order to ensure equitable access to care.
Journal ArticleDOI
HIV-related lung cancer: a growing concern?
TL;DR: The development of lung cancer is not associated with a low CD4 cell count, suggesting that immune function has a less central role in these tumours than in Kaposi's sarcoma and primary cerebral lymphomas.
Journal ArticleDOI
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy
Thomas Powles,Michael Staehler,Börje Ljungberg,Karim Bensalah,Steven E. Canfield,Saeed Dabestani,Rachel H. Giles,Fabian Hofmann,Milan Hora,Markus A. Kuczyk,Thomas B. Lam,Lorenzo Marconi,Axel S. Merseburger,Alessandro Volpe,Axel Bex +14 more
TL;DR: The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy.
Journal ArticleDOI
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
Jose Luis Perez-Gracia,Yohann Loriot,Jonathan E. Rosenberg,Thomas Powles,Andrea Necchi,Syed A. Hussain,Rafael Morales-Barrera,Margitta Retz,Günter Niegisch,Ignacio Duran,Christine Theodore,Enrique Grande,Xiaodong Shen,Jingjing Wang,B. Nelson,Christina Louise Derleth,Michiel S. van der Heijden +16 more
TL;DR: Atezolizumab demonstrated comparable efficacy and safety in previously treated patients with mUC across all lines of therapy evaluated, and was active and tolerable no matter how many treatment regimens patients had received.